2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

 

 Permissions and Reprints

Abstract

In 2018, the International Council for Standardization in Haematology (ICSH) published a consensus document providing guidance for laboratories on measuring direct oral anticoagulants (DOACs). Since that publication, several significant changes related to DOACs have occurred, including the approval of a new DOAC by the Food and Drug Administration, betrixaban, and a specific DOAC reversal agent intended for use when the reversal of anticoagulation with apixaban or rivaroxaban is needed due to life-threatening or uncontrolled bleeding, andexanet alfa. In addition, this ICSH Working Party recognized areas where additional information was warranted, including patient population considerations and updates in point-of-care testing. The information in this manuscript supplements our previous ICSH DOAC laboratory guidance document. The recommendations provided are based on (1) information from peer-reviewed publications about laboratory measurement of DOACs, (2) contributing author's personal experience/expert opinion and (3) good laboratory practice.

Publication History

Received: 01 December 2020

Accepted: 17 March 2021

Accepted Manuscript online:
19 March 2021

Article published online:
30 May 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Gosselin RC, Adcock DM, Bates SM. et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2018; 118 (03) 437-450
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 European Medicines Agency. Ondexxya: Summary of Product Characteristics. 2021 . Accessed March 3, 2021 at: https://www.ema.europa.eu/en/medicines/human/EPAR/ondexxya
  PubMedGoogle Scholar
• 3 Food and Drug Administration. Andexxa: Prescribing Information. 2018 . Accessed March 3, 2021 at: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/andexxa-coagulation-factor-xa-recombinant-inactivated-zhzo
  PubMedGoogle Scholar
• 4 Witt DM, Nieuwlaat R, Clark NP. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2018; 2 (22) 3257-3291
  CrossrefPubMedGoogle Scholar
• 5 Steffel J, Verhamme P, Potpara TS. et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 (16) 1330-1393
  CrossrefPubMedGoogle Scholar
• 6 Douxfils J, Ageno W, Samama CM. et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 2018; 16 (02) 209-219
  CrossrefPubMedGoogle Scholar
• 7 Ruff CT, Giugliano RP, Braunwald E. et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015; 385 (9984): 2288-2295
  CrossrefPubMedGoogle Scholar
• 8 Reilly PA, Lehr T, Haertter S. et al; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63 (04) 321-328
  CrossrefPubMedGoogle Scholar
• 9 Zhang L, Yan X, Fox KAA. et al. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. J Thromb Thrombolysis 2020; 50 (01) 20-29
  CrossrefPubMedGoogle Scholar
• 10 Reinecke I, Solms A, Willmann S. et al. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. J Thromb Thrombolysis 2020; 50 (01) 12-19
  CrossrefPubMedGoogle Scholar
• 11 Solms A, Willmann S, Reinecke I. et al. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. J Thromb Thrombolysis 2020; 50 (01) 1-11
  CrossrefPubMedGoogle Scholar
• 12 Toorop MMA, Lijfering WM, Scheres LJJ. The relationship between DOAC levels and clinical outcomes: the measures tell the tale. J Thromb Haemost 2020; 18 (12) 3163-3168
  CrossrefPubMedGoogle Scholar
• 13 Douxfils J, Mullier F, Dogné JM. Dose tailoring of dabigatran etexilate: obvious or excessive?. Expert Opin Drug Saf 2015; 14 (08) 1283-1289
  CrossrefPubMedGoogle Scholar
• 14 Kato ET, Giugliano RP, Ruff CT. et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc 2016; 5 (05) e003432
  CrossrefPubMedGoogle Scholar
• 15 Buckley LF, Rybak E, Aldemerdash A, Cheng JW, Fanikos J. Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age. Clin Cardiol 2017; 40 (01) 46-52
  CrossrefPubMedGoogle Scholar
• 16 Chan KE, Giugliano RP, Patel MR. et al. Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol 2016; 67 (24) 2888-2899
  CrossrefPubMedGoogle Scholar
• 17 Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI. Subcommittee on Control of Anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (03) 623-627
  CrossrefPubMedGoogle Scholar
• 18 Lindhoff-Last E. Direct oral anticoagulants (DOAC): management of emergency situations. Hamostaseologie 2017; 37 (04) 257-266
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Gendron N, Gay J, Lemoine M, Gaussem P, Lillo-Le-Louet A, Smadja DM. Usefulness of initial plasma dabigatran concentration to predict rebound after reversal. Haematologica 2018; 103 (05) e226-e229
  CrossrefPubMedGoogle Scholar
• 20 Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply. J Thromb Haemost 2016; 14 (12) 2559-2561
  CrossrefPubMedGoogle Scholar
• 21 Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures. J Thromb Haemost 2016; 14 (07) 1325-1327
  CrossrefPubMedGoogle Scholar
• 22 Tripodi A, Marongiu F, Moia M. et al. The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures. Intern Emerg Med 2018; 13 (07) 1029-1036
  CrossrefPubMedGoogle Scholar
• 23 Albaladejo P, Bonhomme F, Blais N. et al; French Working Group on Perioperative Hemostasis (GIHP). Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP) - September 2015. Anaesth Crit Care Pain Med 2017; 36 (01) 73-76
  CrossrefPubMedGoogle Scholar
• 24 Rimsans J, Douxfils J, Smythe MA. et al. Overview and practical application of coagulation assays in managing anticoagulation with direct oral anticoagulants (DOACs). Curr Pharmacol Rep 2020; 6: 241-259
  CrossrefPubMedGoogle Scholar
• 25 Shaw JR, Li N, Vanassche T. et al. Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. Blood Adv 2020; 4 (15) 3520-3527
  CrossrefPubMedGoogle Scholar
• 26 Douketis JD, Spyropoulos AC, Duncan J. et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med 2019; 179 (11) 1469-1478
  CrossrefPubMedGoogle Scholar
• 27 Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (06) 1308-1313
  CrossrefPubMedGoogle Scholar
• 28 Moll S, Crona DJ, Martin K. Direct oral anticoagulants in extremely obese patients: OK to use?. Res Pract Thromb Haemost 2018; 3 (02) 152-155
  CrossrefPubMedGoogle Scholar
• 29 Testa S, Legnani C, Antonucci E. et al; Coordinator of START2-Register. Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost 2019; 17 (07) 1064-1072
  CrossrefPubMedGoogle Scholar
• 30 Testa S, Paoletti O, Legnani C. et al. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost 2018; 16 (05) 842-848
  CrossrefPubMedGoogle Scholar
• 31 Salmonson T, Dogné JM, Janssen H, Garcia Burgos J, Blake P. Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: views from a workshop at the European Medicines Agency (EMA). Eur Heart J Cardiovasc Pharmacother 2017; 3 (01) 42-47
  CrossrefPubMedGoogle Scholar
• 32 Willmann S, Thelen K, Kubitza D. et al. Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study. Thromb J 2018; 16: 32
  CrossrefPubMedGoogle Scholar
• 33 Rahman M, George C, Monagle P. Hot topics in coagulation testing: important considerations for testing children for bleeding/thrombotic disorders. Int J Lab Hematol 2020; 42 (Suppl. 01) 68-74
  CrossrefPubMedGoogle Scholar
• 34 Gosselin R, Douxfils J. Measuring direct oral anticoagulants. In: Favaloro EJ, Lippi G. eds. Hemostasis and Thrombosis. New York, NY: Humana Press; 2017: 217-225
  Google Scholar
• 35 Gosselin RC, Douxfils J. Ecarin based coagulation testing. Am J Hematol 2020; 95 (07) 863-869
  CrossrefPubMedGoogle Scholar
• 36 Gosselin RC, Gosselin R, Douxfils J, Adcock D. Clinical pearls: laboratory assessments of direct oral anticoagulants (DOACS). Hamostaseologie 2017; 37 (04) 295-301
  Article in Thieme ConnectPubMedGoogle Scholar
• 37 Siriez R, Dogné JM, Gosselin R, Laloy J, Mullier F, Douxfils J. Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: practical recommendations for the laboratory. Int J Lab Hematol 2021; 43 (01) 7-20
  CrossrefPubMedGoogle Scholar
• 38 Godier A, Martin AC, Lessire S, Mullier F, Leblanc I, Gouin-Thibault I. Concentrations of direct oral anticoagulants according to guidelines for the periprocedural management of low bleeding risk procedures. Anaesth Crit Care Pain Med 2020; 39 (01) 121-122
  CrossrefPubMedGoogle Scholar
• 39 Sevenet PO, Cucini V, Hervé T. et al. Evaluation of DOAC Filter, a new device to remove direct oral anticoagulants from plasma samples. Int J Lab Hematol 2020; 42 (05) 636-642
  CrossrefPubMedGoogle Scholar
• 40 Kopytek M, Ząbczyk M, Malinowski KP, Undas A, Natorska J. DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients. Clin Chem Lab Med 2020; 58 (03) 430-437
  CrossrefPubMedGoogle Scholar
• 41 Exner T, Rigano J, Favaloro EJ. The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays. Int J Lab Hematol 2020; 42 (Suppl. 01) 41-48
  CrossrefPubMedGoogle Scholar
• 42 Platton S, Hunt C. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban. Int J Lab Hematol 2019; 41 (02) 227-233
  CrossrefPubMedGoogle Scholar
• 43 Jourdi G, Delrue M, Stepanian A. et al. Potential usefulness of activated charcoal (DOAC remove®) for dRVVT testing in patients receiving direct oral anticoagulants. Thromb Res 2019; 184: 86-91
  CrossrefPubMedGoogle Scholar
• 44 Exner T, Favresse J, Lessire S, Douxfils J, Mullier F. Clotting test results correlate better with DOAC concentrations when expressed as a “correction ratio”; results before/after extraction with the DOAC Stop reagent. Thromb Res 2019; 179: 69-72
  CrossrefPubMedGoogle Scholar
• 45 Exner T, Ahuja M, Ellwood L. Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging anticoagulants. Clin Chem Lab Med 2019; 57 (05) 690-696
  CrossrefPubMedGoogle Scholar
• 46 Cox-Morton S, MacDonald S, Thomas W. A diagnostic solution for haemostasis laboratories for patients taking direct oral anticoagulants using DOAC-Remove. Br J Haematol 2019; 187 (03) 377-385
  CrossrefPubMedGoogle Scholar
• 47 Exner T, Michalopoulos N, Pearce J, Xavier R, Ahuja M. Simple method for removing DOACs from plasma samples. Thromb Res 2018; 163: 117-122
  CrossrefPubMedGoogle Scholar
• 48 De Kesel PM, Devreese KMJ. Direct oral anticoagulant adsorption: impact on lupus anticoagulant testing: review of the literature and evaluation on spiked and patient samples. J Thromb Haemost 2020; 18 (08) 2003-2017
  CrossrefPubMedGoogle Scholar
• 49 Ząbczyk M, Kopytek M, Natorska J, Undas A. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants. Clin Chem Lab Med 2019; 57 (09) 1374-1381
  CrossrefPubMedGoogle Scholar
• 50 Monteyne T, De Kesel P, Devreese KMJ. Interference of DOAC Stop and DOAC Remove in the thrombin generation assay and coagulation assays. Thromb Res 2020; 192: 96-99
  CrossrefPubMedGoogle Scholar
• 51 Kopatz WF, Brinkman HJM, Meijers JCM. Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay. Thromb Res 2018; 170: 97-101
  CrossrefPubMedGoogle Scholar
• 52 Bouvy C, Evrard J, Siriez R. et al. P220: Removal of DOACs from plasma: performance comparison and pre-analytical considerations of three different devices. ECTH 2018. Abstract Book 2018
  PubMedGoogle Scholar
• 53 Depreter B, Devreese KM. Dilute Russell's viper venom time reagents in lupus anticoagulant testing: a well-considered choice. Clin Chem Lab Med 2017; 55 (01) 91-101
  CrossrefPubMedGoogle Scholar
• 54 Hillarp A, Strandberg K, Gustafsson KM, Lindahl TL. Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays. J Thromb Haemost 2020; 18 (08) 1866-1873
  CrossrefPubMedGoogle Scholar
• 55 Sokol J, Nehaj F, Ivankova J, Mokan M, Mokan M. First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation. J Thromb Thrombolysis 2018; 46 (03) 393-398
  CrossrefPubMedGoogle Scholar
• 56 Perzborn E, Heitmeier S, Laux V. Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in vitro and in vivo studies. J Cardiovasc Pharmacol Ther 2015; 20 (06) 554-562
  CrossrefPubMedGoogle Scholar
• 57 Shimizu M, Natori T, Tsuda K. et al. Thrombin-induced platelet aggregation: effect of dabigatran using automated platelet aggregometry. Platelets 2020; 31 (03) 360-364
  CrossrefPubMedGoogle Scholar
• 58 Jourdi G, Bachelot-Loza C, Mazoyer E. et al. Effect of rivaroxaban and dabigatran on platelet functions: in vitro study. Thromb Res 2019; 183: 159-162
  CrossrefPubMedGoogle Scholar
• 59 Königsbrügge O, Weigel G, Quehenberger P, Pabinger I, Ay C. Plasma clot formation and clot lysis to compare effects of different anticoagulation treatments on hemostasis in patients with atrial fibrillation. Clin Exp Med 2018; 18 (03) 325-336
  CrossrefPubMedGoogle Scholar
• 60 Carter RLR, Talbot K, Hur WS. et al. Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity. J Thromb Haemost 2018; 16 (11) 2276-2288
  CrossrefPubMedGoogle Scholar
• 61 Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2010; 8 (04) 790-798
  CrossrefPubMedGoogle Scholar
• 62 Semeraro F, Incampo F, Ammollo CT. et al. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation. Thromb Res 2016; 138: 22-29
  CrossrefPubMedGoogle Scholar
• 63 Douxfils J, Tamigniau A, Chatelain B, Goffinet C, Dogné JM, Mullier F. Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J 2014; 12: 24
  CrossrefPubMedGoogle Scholar
• 64 Macedo KA, Tatarian P, Eugenio KR. Influence of direct oral anticoagulants on anti-factor Xa measurements utilized for monitoring heparin. Ann Pharmacother 2018; 52 (02) 154-159
  CrossrefPubMedGoogle Scholar
• 65 Sairaku A, Nakano Y, Onohara Y. et al. Residual anticoagulation activity in atrial fibrillation patients with temporary interrupted direct oral anticoagulants: comparisons across 4 drugs. Thromb Res 2019; 183: 119-123
  CrossrefPubMedGoogle Scholar
• 66 Evrard J, Hardy M, Dogné JM. et al. Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing. Int J Lab Hematol 2021; 43 (01) e48-e51
  CrossrefPubMedGoogle Scholar
• 67 Reda S, Morimont L, Douxfils J, Rühl H. Can we measure the individual prothrombotic or prohemorrhagic tendency by global coagulation tests?. Hamostaseologie 2020; 40 (03) 364-378
  Article in Thieme ConnectPubMedGoogle Scholar
• 68 Douxfils J, Morimont L, Bouvy C. et al. Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application. J Thromb Haemost 2019; 17 (08) 1273-1287
  CrossrefPubMedGoogle Scholar
• 69 Siguret V, Abdoul J, Delavenne X. et al. Rivaroxaban pharmacodynamics in healthy volunteers evaluated with thrombin generation and the active protein C system: modeling and assessing interindividual variability. J Thromb Haemost 2019; 17 (10) 1670-1682
  CrossrefPubMedGoogle Scholar
• 70 Metze M, Pfrepper C, Klöter T. et al. Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulants. Res Pract Thromb Haemost 2020; 4 (04) 610-618
  CrossrefPubMedGoogle Scholar
• 71 Pfrepper C, Metze M, Siegemund A, Klöter T, Siegemund T, Petros S. Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system. Res Pract Thromb Haemost 2020; 4 (04) 619-627
  CrossrefPubMedGoogle Scholar
• 72 Hemker HC, Al Dieri R, Béguin S. Heparins: a shift of paradigm. Front Med (Lausanne) 2019; 6: 254
  CrossrefPubMedGoogle Scholar
• 73 Favresse J, Hardy M, van Dievoet MA. et al. Andexanet alfa for the reversal of factor Xa inhibitors. Expert Opin Biol Ther 2019; 19 (05) 387-397
  CrossrefPubMedGoogle Scholar
• 74 Lu G, DeGuzman FR, Hollenbach SJ. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19 (04) 446-451
  CrossrefPubMedGoogle Scholar
• 75 Siegal DM, Curnutte JT, Connolly SJ. et al. Andexanet alfa for the reversal of factor Xa Inhibitor activity. N Engl J Med 2015; 373 (25) 2413-2424
  CrossrefPubMedGoogle Scholar
• 76 Connolly SJ, Crowther M, Eikelboom JW. et al; ANNEXA-4 Investigators. Full Study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380 (14) 1326-1335
  CrossrefPubMedGoogle Scholar
• 77 European Medicines Agency. Praxbind: Summary of Product Characeteristics. 2021 . Accessed February 22, 2021 at: https://www.ema.europa.eu/documents/product-information/praxbind-epar-product-information_en.pdf
  PubMedGoogle Scholar
• 78 Food and Drug Administration. Praxbind: Prescribing Information. Accessed February 23, 2021 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761025s002lbl.pdf
  PubMedGoogle Scholar
• 79 Pollack Jr CV, Reilly PA, van Ryn J. et al. Idarucizumab for dabigatran reversal: full cohort analysis. N Engl J Med 2017; 377 (05) 431-441
  CrossrefPubMedGoogle Scholar
• 80 Gendron N, Chocron R, Billoir P. et al. Dabigatran level before reversal can predict hemostatic effectiveness of idarucizumab in a real-world setting. Front Med (Lausanne) 2020; 7: 599626
  CrossrefPubMedGoogle Scholar
• 81 Gendron N, Feral-Pierssens AL, Jurcisin I. et al. Real-world use of idarucizumab for dabigatran reversal in three cases of serious bleeding. Clin Case Rep 2017; 5 (03) 346-350
  CrossrefPubMedGoogle Scholar
• 82 Singh S, Nautiyal A, Belk KW. Real world outcomes associated with idarucizumab: population-based retrospective cohort study. Am J Cardiovasc Drugs 2020; 20 (02) 161-168
  CrossrefPubMedGoogle Scholar
• 83 van der Wall SJ, van Rein N, van den Bemt B. et al. Performance of idarucizumab as antidote of dabigatran in daily clinical practice. Europace 2019; 21 (03) 414-420
  CrossrefPubMedGoogle Scholar
• 84 Kermer P, Eschenfelder CC, Diener HC. et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-Updated series of 120 cases. Int J Stroke 2020; 15 (06) 609-618
  CrossrefPubMedGoogle Scholar
• 85 Connolly SJ, Milling Jr TJ, Eikelboom JW. et al; ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375 (12) 1131-1141
  CrossrefPubMedGoogle Scholar
• 86 Hunt BJ, Neal MD, Stensballe J. Reversing anti-factor Xa agents and the unmet needs in trauma patients. Blood 2018; 132 (23) 2441-2445
  CrossrefPubMedGoogle Scholar
• 87 Connors JM. Testing and monitoring direct oral anticoagulants. Blood 2018; 132 (19) 2009-2015
  CrossrefPubMedGoogle Scholar
• 88 European Medicines Agency. Direct Health Care Professional Communication (DHCP): Ondexxya (Andexanet Alfa): Commercial Anti-FXa Activity Assays Are Unsuitable for Measuring Anti-FXa Activity Following Administration of Andexanet Alfa. Accessed October 18, 2020 at: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/direct-healthcare-professional-communications
  PubMedGoogle Scholar
• 89 Barra ME, Das AS, Hayes BD. et al. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. J Thromb Haemost 2020; 18 (07) 1637-1647
  CrossrefPubMedGoogle Scholar
• 90 Barzilai M, Kirgner I, Steimatzky A. et al. Prothrombin complex concentrate before urgent surgery in patients treated with rivaroxaban and apixaban. Acta Haematol 2020; 143 (03) 266-271
  CrossrefPubMedGoogle Scholar
• 91 Bavalia R, Abdoellakhan R, Brinkman HJM. et al. Emergencies on direct oral anticoagulants: management, outcomes, and laboratory effects of prothrombin complex concentrate. Res Pract Thromb Haemost 2020; 4 (04) 569-581
  CrossrefPubMedGoogle Scholar
• 92 Giffard-Quillon L, Desmurs-Clavel H, Grange C, Jourdy Y, Dargaud Y. Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?. Thromb J 2020; 18: 15
  CrossrefPubMedGoogle Scholar
• 93 Shaw JR, Carrier M, Dowlatshahi D. et al. Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: hemostatic and thrombotic outcomes. Thromb Res 2020; 195: 21-28
  CrossrefPubMedGoogle Scholar
• 94 Lindhoff-Last E, Herrmann E, Lindau S. et al. Severe hemorrhage associated with oral anticoagulants. Dtsch Arztebl Int 2020; 117 (18) 312-319
  PubMedGoogle Scholar
• 95 Hindricks G, Potpara T, Dagres N. et al; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021; 42 (05) 373-498
  CrossrefPubMedGoogle Scholar
• 96 Patel JP, Byrne RA, Patel RK, Arya R. Progress in the monitoring of direct oral anticoagulant therapy. Br J Haematol 2019; 184 (06) 912-924
  CrossrefPubMedGoogle Scholar
• 97 Favaloro EJ, Lippi G. Recent advances in mainstream hemostasis diagnostics and coagulation testing. Semin Thromb Hemost 2019; 45 (03) 228-246
  Article in Thieme ConnectPubMedGoogle Scholar
• 98 Jigar Panchal H, Kent NJ, Knox AJS, Harris LF. Microfluidics in haemostasis: a review. Molecules 2020; 25 (04) E833
  CrossrefPubMedGoogle Scholar
• 99 Alouidor B, Sweeney RE, Tat T, Wong RK, Yoon JY. Microfluidic point-of-care ecarin-based clotting and chromogenic assays for monitoring direct thrombin inhibitors. J Extra Corpor Technol 2019; 51 (01) 29-37
  CrossrefPubMedGoogle Scholar
• 100 Frydman GH, Ellett F, Van Cott EM. et al. A new test for the detection of direct oral anticoagulants (rivaroxaban and apixaban) in the emergency room setting. Crit Care Explor 2019; 1 (08) e0024
  CrossrefPubMedGoogle Scholar
• 101 Ansell J, Zappe S, Jiang X. et al. A novel whole blood point-of-care coagulometer to measure the effect of direct oral anticoagulants and heparins. Semin Thromb Hemost 2019; 45 (03) 259-263
  Article in Thieme ConnectPubMedGoogle Scholar
• 102 Harder S, Santos SMD, Krozer V, Moll J. Surface acoustic wave-based microfluidic coagulation device for monitoring anticoagulant therapy. Semin Thromb Hemost 2019; 45 (03) 253-258
  Article in Thieme ConnectPubMedGoogle Scholar
• 103 Artang R, Anderson M, Nielsen JD. Fully automated thromboelastograph TEG 6s to measure anticoagulant effects of direct oral anticoagulants in healthy male volunteers. Res Pract Thromb Haemost 2019; 3 (03) 391-396
  CrossrefPubMedGoogle Scholar
• 104 Dias JD, Lopez-Espina CG, Ippolito J. et al. Rapid point-of-care detection and classification of direct-acting oral anticoagulants with the TEG 6s: implications for trauma and acute care surgery. J Trauma Acute Care Surg 2019; 87 (02) 364-370
  CrossrefPubMedGoogle Scholar
• 105 Bliden KP, Chaudhary R, Mohammed N. et al. Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. J Thromb Thrombolysis 2017; 43 (04) 437-445
  CrossrefPubMedGoogle Scholar
• 106 Harenberg J, Beyer-Westendorf J, Crowther M. et al; Working Group Members. Accuracy of a rapid diagnostic test for the presence of direct oral factor Xa or thrombin inhibitors in urine: a multicenter trial. Thromb Haemost 2020; 120 (01) 132-140
  Article in Thieme ConnectPubMedGoogle Scholar
• 107 Harenberg J, Schreiner R, Hetjens S, Weiss C. Detecting anti-IIa and anti-Xa direct oral anticoagulant (DOAC) agents in urine using a DOAC dipstick. Semin Thromb Hemost 2019; 45 (03) 275-284
  Article in Thieme ConnectPubMedGoogle Scholar
• 108 Foerster KI, Huppertz A, Meid AD. et al. Dried-blood-spot technique to monitor direct oral anticoagulants: clinical validation of a UPLC-MS/MS-based assay. Anal Chem 2018; 90 (15) 9395-9402
  CrossrefPubMedGoogle Scholar
• 109 Protti M, Mandrioli R, Mercolini L. Tutorial: volumetric absorptive microsampling (VAMS). Anal Chim Acta 2019; 1046: 32-47
  CrossrefPubMedGoogle Scholar
• 110 Douxfils J, Pochet L, Lessire S. et al. Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless?. Trends Analyt Chem 2016; 84: 41-50
  CrossrefPubMedGoogle Scholar
• 111 Bonar R, Favaloro EJ, Mohammed S. et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 2016; 48 (01) 60-71
  CrossrefPubMedGoogle Scholar
• 112 Bonar R, Favaloro EJ, Mohammed S, Pasalic L, Sioufi J, Marsden K. The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples. Pathology 2015; 47 (04) 355-364
  CrossrefPubMedGoogle Scholar
• 113 Hollestelle MJ, Meijer P. International external quality assessment for measurements of direct oral anticoagulants: results and recommendations. Br J Haematol 2020; 188 (03) 460-464
  CrossrefPubMedGoogle Scholar
• 114 Jennings I, Kitchen D, Kitchen S, Woods T, Walker I. The importance of commutability in material used for quality control purposes. Int J Lab Hematol 2019; 41 (01) 39-45
  CrossrefPubMedGoogle Scholar
• 115 Van Blerk M, Bailleul E, Chatelain B. et al. Influence of apixaban on commonly used coagulation assays: results from the Belgian National External Quality Assessment Scheme. Int J Lab Hematol 2017; 39 (04) 402-408
  CrossrefPubMedGoogle Scholar
• 116 Van Blerk M, Bailleul E, Chatelain B. et al. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost 2015; 113 (01) 154-164
  Article in Thieme ConnectPubMedGoogle Scholar
• 117 Van Cott EM, Smock KJ, Chen D, Hsu P, Zantek ND, Meijer P. Testing for dabigatran and rivaroxaban by clinical laboratories. Am J Hematol 2016; 91 (11) E464-E467
  CrossrefPubMedGoogle Scholar
• 118 Smock KJ, Moser KA. What have we learned from coagulation laboratory participation in external quality programs?. Int J Lab Hematol 2019; 41 (Suppl. 01) 49-55
  CrossrefPubMedGoogle Scholar
• 119 Testa S, Legnani C, Tripodi A. et al. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study. J Thromb Haemost 2016; 14 (11) 2194-2201
  CrossrefPubMedGoogle Scholar
• 120 Favaloro EJ, Gilmore G, Arunachalam S, Mohammed S, Baker R. Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): a comparative study using DOAC Stop and andexanet alfa. Thromb Res 2019; 180: 10-19
  CrossrefPubMedGoogle Scholar
• 121 Halton J, Brandão LR, Luciani M. et al; DIVERSITY Trial Investigators. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol 2021; 8 (01) e22-e33
  CrossrefPubMedGoogle Scholar
• 122 Connor P, Sánchez van Kammen M, Lensing AWA. et al. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Adv 2020; 4 (24) 6250-6258
  CrossrefPubMedGoogle Scholar
• 123 Thom K, Lensing AWA, Nurmeev I. et al. Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). Blood Adv 2020; 4 (19) 4632-4639
  CrossrefPubMedGoogle Scholar
• 124 Janssen MD. Use of XARELTO in Pediatric Patients. 2020 . Accessed March 3, 2021 Mar at: https://www.janssenmd.com/xarelto/special-populations/pediatrics/use-of-xarelto-in-pediatric-patients
  PubMedGoogle Scholar
• 125 Payne RM, Burns KM, Glatz AC. et al; Pediatric Heart Network Investigators. A multi-national trial of a direct oral anticoagulant in children with cardiac disease: design and rationale of the Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) study. Am Heart J 2019; 217: 52-63
  CrossrefPubMedGoogle Scholar
• 126 O'Brien SH, Li D, Mitchell LG. et al. PREVAPIX-ALL: apixaban compared to standard of care for prevention of venous thrombosis in paediatric acute lymphoblastic leukaemia (ALL): rationale and design. Thromb Haemost 2019; 119 (05) 844-853
  Article in Thieme ConnectPubMedGoogle Scholar
• 127 Lippi G, Gosselin R, Favaloro EJ. Current and emerging direct oral anticoagulants: state-of-the-art. Semin Thromb Hemost 2019; 45 (05) 490-501
  Article in Thieme ConnectPubMedGoogle Scholar
• 128 European Medicines Agency. Eliquis - Summary of Product Characteristics. 2021 . Accessed February 21, 2021 at: https://www.ema.europa.eu/documents/product-information/eliquis-epar-product-information_en.pdf
  PubMedGoogle Scholar
• 129 European Medicines Agency. Pradaxa: Summary of Product Characteristics. 2021 . Accessed February 21, 2021 at: https://www.ema.europa.eu/documents/product-information/pradaxa-epar-product-information_en.pdf
  PubMedGoogle Scholar
• 130 European Medicines Agency. Xarelto: Summary of Product Characteristics. 2021 . Accessed February 21, 2021 at: https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf
  PubMedGoogle Scholar
• 131 Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014; 53 (01) 1-16
  CrossrefPubMedGoogle Scholar
• 132 Weitz JI, Connolly SJ, Patel I. et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010; 104 (03) 633-641
  Article in Thieme ConnectPubMedGoogle Scholar
• 133 Verhamme P, Wells PS, Segers A. et al. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost 2016; 116 (04) 747-753
  Article in Thieme ConnectPubMedGoogle Scholar